Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E J Small

Showing results (41-50 of 86) with videos related to

Pageof 9
Sort By:
Seminars in Oncology|October 31, 2001
Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancerE J Small, R Bok, D M Reese, et al.
Seminars in Oncology|December 1, 1996
Cancer and Leukemia Group B trials for advanced prostate cancerE J Small, N A Dawson, P W Kantoff, et al.
Cancer|October 15, 1996
A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urotheliumE J Small, L J Fippin, M L Ernest, et al.
Journal of Surgical Oncology|January 1, 1994
Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimensJ S Wolf, F R Aronson, E J Small, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 27, 2009
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102G K Philips, S Halabi, B L Sanford, et al.
Urology|August 8, 2001
Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancerG D Grossfeld, U B Chaudhary, D M Reese, et al.
Urology|February 2, 2000
Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: a retrospective analysisV S Tigrani, D M Reese, E J Small, et al.
American Journal of Clinical Pathology|August 8, 2001
HER2 protein expression and gene amplification in androgen-independent prostate cancerD M Reese, E J Small, G Magrane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factorE J Small, D M Reese, B Um, et al.
Prostate Cancer and Prostatic Diseases|July 23, 2014
Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetateW Kim, J O Jones, M Diamond, et al.
Pageof 9

Showing results (41-50 of 86) with videos related to

Sort By:
Pageof 9
Seminars in Oncology|October 31, 2001
Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancerE J Small, R Bok, D M Reese, et al.
Seminars in Oncology|December 1, 1996
Cancer and Leukemia Group B trials for advanced prostate cancerE J Small, N A Dawson, P W Kantoff, et al.
Cancer|October 15, 1996
A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urotheliumE J Small, L J Fippin, M L Ernest, et al.
Journal of Surgical Oncology|January 1, 1994
Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimensJ S Wolf, F R Aronson, E J Small, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 27, 2009
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102G K Philips, S Halabi, B L Sanford, et al.
Urology|August 8, 2001
Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancerG D Grossfeld, U B Chaudhary, D M Reese, et al.
Urology|February 2, 2000
Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: a retrospective analysisV S Tigrani, D M Reese, E J Small, et al.
American Journal of Clinical Pathology|August 8, 2001
HER2 protein expression and gene amplification in androgen-independent prostate cancerD M Reese, E J Small, G Magrane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factorE J Small, D M Reese, B Um, et al.
Prostate Cancer and Prostatic Diseases|July 23, 2014
Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetateW Kim, J O Jones, M Diamond, et al.
Pageof 9